Purchase this article with an account.
Philip A. Petrou, Denise Cunningham, Katherine Shimel, Molly Harrington, Keri Hammel, Catherine A. Cukras, Frederick L. Ferris, Emily Y. Chew, Wai T. Wong; Intravitreal Sirolimus for the Treatment of Geographic Atrophy: Results of a Phase I/II Clinical Trial. Invest. Ophthalmol. Vis. Sci. 2015;56(1):330-338. doi: 10.1167/iovs.14-15877.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the safety and effects of intravitreal sirolimus for the potential treatment of geographic atrophy (GA).
The study was a single-center, open-label, phase I/II trial enrolling six participants with bilateral GA treated with intravitreal sirolimus in only one randomly assigned eye, with the fellow eye as control. The primary efficacy outcome measure was the change in total GA area from baseline on color fundus photography (CFP); secondary outcomes included changes in GA area on fundus autofluorescence (FAF), visual acuity, central retinal thickness (CRT), and macular sensitivity from baseline.
Although no systemic adverse events were attributed to treatment, two of six participants had ocular adverse events that were possibly associated. The treated eye of one participant developed abnormal paralesional changes on FAF that were associated with accelerated retinal thinning. This accelerated retinal thinning was also seen in the treated eye of a second participant. Because of concern that these events were associated with treatment, treatment was suspended. Comparisons of treated and fellow eyes for change in visual acuity, change in GA area, and change in CRT showed no evidence of treatment benefit and generally favored the untreated fellow eye.
While paralesional FAF changes and rapid retinal thinning observed are potentially part of the natural course of GA, they may possibly be related to treatment. No general evidence of anatomical or functional benefit was detected in treated eyes. Further data on intravitreal sirolimus for GA treatment will be available from a larger phase II trial. (ClinicalTrials.gov number, NCT01445548.)
This PDF is available to Subscribers Only